Search

Your search keyword '"Ruperti-Repilado FJ"' showing total 2 results
Start Over Author "Ruperti-Repilado FJ" Topic cardiology and cardiovascular medicine
2 results on '"Ruperti-Repilado FJ"'

1. Clinical outcome of COVID-19 in patients with adult congenital heart disease

Author

Schwerzmann M, Ruperti-Repilado FJ, Baumgartner H, Bouma B, Bouchardy J, Budts W, Campens L, Chessa M, Del Cerro Marin MJ, Gabriel H, Gallego P, Garcia-Orta R, Gonzalez AE, Jensen AS, Ladouceur M, Miranda-Barrio B, Morissens M, Pasquet A, Rueda J, van den Bosch AE, van der Zwaan HB, Tobler D, Greutmann M, EPOCH, Cardiology, ACS - Heart failure & arrhythmias, ACS - Pulmonary hypertension & thrombosis, Schwerzmann, M., Ruperti-Repilado, F. J., Baumgartner, H., Bouma, B., Bouchardy, J., Budts, W., Campens, L., Chessa, M., Del Cerro Marin, M. J., Gabriel, H., Gallego, P., Garcia-Orta, R., Gonzalez, A. E., Jensen, A. S., Ladouceur, M., Miranda-Barrio, B., Morissens, M., Pasquet, A., Rueda, J., Van Den Bosch, A. E., Van Der Zwaan, H. B., Tobler, D., Greutmann, M., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Service de pathologie cardiovasculaire, Institut Català de la Salut, [Schwerzmann M, Ruperti-Repilado FJ] Center for Congenital Heart Disease, Inselspital University Hospital, Bern, Switzerland. Dept. of Cardiology III - Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Munster, Nordrhein-Westfalen, Germany. [Baumgartner H] Dept. of Cardiology III - Adult Congenital and Valvular Heart Disease, University Hospital Muenster, Munster, Nordrhein-Westfalen, Germany. [Bouma B] Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands. [Bouchardy J] Department of Cardiology and Cardiac Surgery, Lausanne University Hospital, Lausanne, Switzerland. Division of Cardiology, University Hospital of Geneva, Geneva, Switzerland. [Budts W] Congenital and Structural Cardiology, University Hospital Leuven, Leuven, Flanders, Belgium. Department of Cardiovascular Sciences, Catholic University Leuven, Leuven, Flanders, Belgium. [Miranda-Barrio B] Unitat de Cardiopaties Congènites de l’Adult, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Santa Creu i Sant Pau University Hospital, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Inotrope, Pediatrics, medicine.medical_specialty, Cardiac & Cardiovascular Systems, Heart disease, Coronavirus disease 2019 (COVID-19), Cardiopatia congènita, Cardiologie et circulation, 610 Medicine & health, 030204 cardiovascular system & hematology, Logistic regression, 03 medical and health sciences, 0302 clinical medicine, Natural Science Disciplines::Science::Research::Biomedical Research::Outcome Assessment (Health Care) [DISCIPLINES AND OCCUPATIONS], SDG 3 - Good Health and Well-being, medicine, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicine and Health Sciences, 030212 general & internal medicine, congenital, heart defects, POPULATION, COVID-19 (Malaltia) - Complicacions, Science & Technology, business.industry, DEATH, congenital, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], CARE, medicine.disease, Obesity, Eisenmenger syndrome, disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica::evaluación del desenlace (asistencia sanitaria) [DISCIPLINAS Y OCUPACIONES], Cohort, Avaluació de resultats (Assistència sanitària), Cardiovascular System & Cardiology, heart defects, business, Cardiology and Cardiovascular Medicine, Body mass index, Life Sciences & Biomedicine, Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Congenital Abnormalities::Cardiovascular Abnormalities::Heart Defects, Congenital [DISEASES], enfermedades y anomalías neonatales congénitas y hereditarias::anomalías congénitas::anomalías cardiovasculares::cardiopatías congénitas [ENFERMEDADES]
Abstract

[Aims] Patients with adult congenital heart disease (ACHD) are a potentially vulnerable patient cohort in case of COVID-19. Some cardiac defects may be associated with a poor COVID-19 outcome. Risk estimation in ACHD is currently based on expert opinion. The aim of this study was to collect clinical outcome data and to identify risk factors for a complicated course of COVID-19 in patients with ACHD., [Methods] Twenty-five ACHD centres in nine European countries participated in the study. Consecutive patients with ACHD diagnosed with COVID-19 presenting to one of the participating centres between 27 March and 6 June 2020 were included. A complicated disease course was defined as hospitalisation for COVID-19 requiring non-invasive or invasive ventilation and/or inotropic support, or a fatal outcome., [Results] Of 105 patients with a mean age of 38±13 years (58% women), 13 had a complicated disease course, of whom 5 died. In univariable analysis, age (OR 1.3, 95% CI 1.1 to 1.7, per 5 years), ≥2 comorbidities (OR 7.1, 95% CI 2.1 to 24.5), body mass index of >25 kg/m2 (OR 7.2, 95% CI 1.9 to 28.3) and cyanotic heart disease (OR 13.2, 95% CI 2.5 to 68.4) were associated with a complicated disease course. In a multivariable logistic regression model, cyanotic heart disease was the most important predictor (OR 60.0, 95% CI 7.6 to 474.0)., [Conclusions] Among patients with ACHD, general risk factors (age, obesity and multiple comorbidities) are associated with an increased risk of complicated COVID-19 course. Congenital cardiac defects at particularly high risk were cyanotic lesions, including unrepaired cyanotic defects or Eisenmenger syndrome., The European Collaboration for Prospective Outcome Research in Congenital Heart Disease is funded by internal grants without support from the pharmaceutical industry.

Published
2021
Full Text
View/download PDF

2. Risk stratification of adults with congenital heart disease during the COVID-19 pandemic: insights from a multinational survey among European experts

Author

Markus Schwerzmann, Marielle Morissens, Matthias Greutmann, Pastora Gallego, Annette Schophuus Jensen, Massimo Chessa, Daniel Tobler, Gerhard Diller, Francisco Javier Ruperti-Repilado, Berto Bouma, Judith Bouchardy, Harald Gabriel, Agnes Pasquet, Rocío García Orta, María Elvira, Rodríguez-Monte Garrido-Lestache, Elvira Ana González, Pablo Meras, Berta Miranda, Joaquin Rueda Soriano, Oktay Tutare, Annemien van den Bosch, Heleen van der Zwaan, Institut Català de la Salut, [Ruperti-Repilado FJ] Center for Congenital Heart Disease, Cardiology, Inselspital University Hospital Bern, University of Bern, Bern, Switzerland. [Tobler D] Division of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland. [Greutmann M] University Heart Centre Zurich, Department of Cardiology, University of Zurich, Zurich, Switzerland. [Bouchardy J] Cardiovascular Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Service de Cardiologie, University Hospital of Geneva, Geneve, Switzerland. [Ladouceur M] Adult Congenital Heart Disease Unit, Centre de Référence des Malformations Cardiaques Congénitales Complexes, M3C, Inserm U970, Paris Centre de Recherche Cardiovasculaire, Hôpital Europeen Georges-Pompidou Pôle Cardio-vasculaire Rénal Métabolique, Paris, France. [Dos-Subira L] Unitat Integrada de Cardiopaties Congènites de l'Adolescent i l'Adult, Vall d'Hebron Hospital Universitari, Barcelona, Spain - Sant Pau. CIBERCV, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, University of Zurich, Schwerzmann, Markus, Cardiology, ACS - Heart failure & arrhythmias, and ACS - Pulmonary hypertension & thrombosis

Subjects
Heart disease, Cardiopatia congènita, Fontan Procedure, Riscos per a la salut - Avaluació, Risk Factors, Surveys and Questionnaires, Pandemic, Outcome Assessment, Health Care, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Pandèmia de COVID-19, 2020, enfermedades cardiovasculares::anomalías cardiovasculares::cardiopatías congénitas [ENFERMEDADES], 610 Medicine & health, Societies, Medical, COVID, Pulmonary Arterial Hypertension, global burden of disease, Congenital Heart Disease, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Prognosis, health care, Europe, técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::evaluación de riesgos [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Editorial, Risk stratification, 10209 Clinic for Cardiology, heart defects, Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Assessment [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Cardiology and Cardiovascular Medicine, Adult, Heart Defects, Congenital, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Cardiovascular Diseases::Cardiovascular Abnormalities::Heart Defects, Congenital [DISEASES], Risk Assessment, 2705 Cardiology and Cardiovascular Medicine, medicine, Humans, Diseases of the circulatory (Cardiovascular) system, outcome assessment, Pandemics, Estimation, business.industry, SARS-CoV-2, congenital, COVID-19, Fontan physiology, Eisenmenger Complex, medicine.disease, Eisenmenger syndrome, RC666-701, Emergency medicine, Observational study, Perception, business
Abstract

[Objective] Adults with congenital heart disease (ACHD) may be at a higher risk of a fatal outcome in case of COVID-19. Current risk stratification among these patients relies on personal experience and extrapolation from patients with acquired heart disease. We aimed to provide an expert view on risk stratification while awaiting results from observational studies., [Methods] This study was an initiative of the EPOCH (European Collaboration for Prospective Outcome Research in Congenital Heart disease). Among nine European countries (Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Spain and Switzerland), 24 experts from 23 tertiary ACHD centres participated in the survey. ACHD experts were asked to identify ACHD-specific COVID-19 risk factors from a list of potential outcome predictors and to estimate the risk of adverse COVID-19 outcomes in seven commonly seen patient scenarios., [Results] 82% of participants did not consider all ACHD patients at risk of COVID-19 related complications. There was a consensus on pulmonary arterial hypertension, Fontan physiology and cyanotic heart disease as risk factors for adverse outcomes. Among different ACHD scenarios, a patient with Eisenmenger syndrome was considered to be at the highest risk. There was a marked variability in risk estimation among the other potential outcome predictors and ACHD scenarios., [Conclusions] Pulmonary arterial hypertension, Fontan palliation and cyanotic heart disease were widely considered as risk factors for poor outcome in COVID-19. However, there was a marked disparity in risk estimation for other clinical scenarios. We are in urgent need of outcome studies in ACHD suffering from COVID-19., EPOCH-ASO is funded by internal grants without support from the pharmaceutical industry.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results